Product Information
BUPROPION HCL XL 150 MG TABLET is a generic product labeled by Rising Pharma Holdings Inc., priced at $0.0785 per EA under NDC 16571086209. Its NADAC has been published 206 times since Oct 26, 2022.
FDA first approved this application on Jan 28, 2019. Its Orange Book therapeutic-equivalence code is AB3 — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
150 mg/1
Manufacturer
Rising Pharma Holdings Inc.NDC
16571086209
Classification
Generic
Dosage Form
TABLET, EXTENDED RELEASE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
BUPROPION HYDROCHLORIDEApproval Type
Generic (ANDA)
FDA Application
ANDA211020FDA Approved
1/28/2019
TE Code
AB3
On Market Since
8/1/2022
Pharmacological Classes
Price Statistics
The NADAC for BUPROPION HCL XL 150 MG TABLET has been published 206 times since Oct 26, 2022, and over the history we have for it it has declined 29.1%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.0785 per EA |
|---|---|
| All-time high | $0.1215 (Apr 10, 2024) |
| All-time low | $0.0745 (Nov 20, 2024) |
| 52-week high | $0.0996 |
| 52-week low | $0.0770 |
| Median price | $0.1013 |
| Average price | $0.0986 |
| Largest weekly change | -30.3% (Nov 20, 2024) |
| Weeks tracked | 206 |
| Tracking since | Oct 26, 2022 |
Generic Alternatives
The matcher finds 14 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 1% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Rising Pharma Holdings Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
bupropion hydrochloride market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Aminoketone class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of BUPROPION HCL XL 150 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for BUPROPION HCL XL 150 MG TABLET, manufactured by Rising Pharma Holdings Inc., is $0.0785 per EA (NDC 16571086209), effective Sep 30, 2026.
How has the price of BUPROPION HCL XL 150 MG TABLET changed over time?
Over the history we have for it, the NADAC for BUPROPION HCL XL 150 MG TABLET has declined 29.1%. It has been tracked across 206 weekly CMS publications since Oct 26, 2022.
What are the highest and lowest recorded NADAC prices for BUPROPION HCL XL 150 MG TABLET?
Since Oct 26, 2022, the NADAC for BUPROPION HCL XL 150 MG TABLET has ranged from a low of $0.0745 (Nov 20, 2024) to a high of $0.1215 (Apr 10, 2024), with a median of $0.1013 per EA.
Are there cheaper alternatives to BUPROPION HCL XL 150 MG TABLET?
Yes. 14 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, BUPROPION HCL XL 150 MG TABLET, is $0.0779 per EA — about 1% below BUPROPION HCL XL 150 MG TABLET.
Who manufactures BUPROPION HCL XL 150 MG TABLET?
BUPROPION HCL XL 150 MG TABLET (NDC 16571086209) is labeled by Rising Pharma Holdings Inc., and CMS classifies it as a generic product.